Fedora Pharmaceuticals Inc.
Developing a second-generation beta-lactamase inhibitor
This article was originally published in Start Up
Executive Summary
In recent decades, both gram-positive and gram-negative bacteria previously susceptible to beta-lactam antibiotics have developed enzymes that render them inactive. Fedora Pharmaceuticals Inc. believes it has identified compounds that may prove able to thwart all four classes of beta-lactamases. Its compounds are meant to be used in combination with existing beta-lactam antibiotics that were historically effective but are no longer.